When it rains it pours for Mallinckrodt (MNK). Last month a Delaware judge invalidated 11 patents pursuant to Inomax, one of the company’s top-selling treatments; it could pave the way for Praxair (PX) to offer a generic version. The Journal
October 15, 2017